TOKYO, June 11, 2018  - Astellas Pharma Inc. (President and CEO: Kenji Yasukawa, Ph.D., “Astellas” ) today announced that it launched 40 mg XTANDI® (generic name enzalutamide) Tablets and 80 mg XTANDI® Tablets in Japan for the treatment of castration-resistant prostate cancer, which add additional dosage forms to the previously available 40 mg XTANDI® Capsules. XTANDI® is an oral androgen receptor signaling inhibitor.

Both the 40 mg XTANDI® Tablets and 80 mg XTANDI® Tablets are smaller in size than the 40 mg XTANDI® Capsules; thus offering a more patient-friendly medication. With the 80 mg tablets, the number of doses taken each time will also be reduced.

As of May 2018, enzalutamide is available in more than 70 countries worldwide. In Japan, XTANDI® Capsules were launched in May 2014 for castration-resistant prostate cancer.

Astellas is pleased to deliver XTANDI® tablets to patients to further enhance its contributions to the treatment of castration-resistant prostate cancer. 

Astellas reflected the impact from this launch in its financial forecasts of the current fiscal year ending March 31, 2019.